Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Bristol-Myers

Cardinal Health

Gilead Sciences

Medtronic

Pfizer

The strong move higher that Nvidia has driven in the stock market this year has been significant, and the world of artificial intelligence has driven stock prices this year.

Big Institutions Grab ‘Strong Buy' Dividend Stocks in a Sector Not Totally Driven by AI

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Cisco Systems

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Home Depot

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Merck

Paychex

Rollins

Schwab US Dividend Equity ETF

Snap-on

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF, with a few minor twists. The portfolio fell by 0.57% in August, outperforming the S&P 500 by 1.02%. Year-to-date, the portfolio is up 14.07%. Since inception, the portfolio is generating 3.95% of alpha over the S&P 500.

4 Factor Dividend Growth Portfolio - Closing In On A Historic First Year

Amcor Plc

Franklin Resources

Colgate-Palmolive

Chevron

Essex Property Trust

Federal Realty Investment Trust

Coca-Cola

NextEra Energy

Realty Income Corp

Sysco

Target

T. Rowe Price Group

Walgreens

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." -- Kiplinger.com/Investing. 66 Aristocrats, screened as of September 1, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 15.58%-45.47% topped-by WBA & NEE. By yield, WBA topped-all Aristocrats. Top-ten Yields from ESS, ABBV, TROW, FRT, BEN, IBM, AMCR, O, MMM, & WBA, averaged 4.99%.

Dividend Aristocrats: 4 Top Dogs Plus 6 Chasers For September

Citigroup

Caterpillar

CVS Health

Citizens & Northern

General Dynamics

Kinder Morgan

National Grid

Norfolk Southern

Norwood Financial

Healthpeak Properties

Premier Financial

Provident Financial Services

Procter & Gamble

Starbucks

AT&T

Texas Instruments

Verizon

WestRock

We invest in dividend stocks to grow passive income and eventually cover monthly expenses for early retirement. We use a stock screener to find undervalued stocks with a strong payout ratio and a history of increasing dividends. In August, we received $1,097 in dividend income, with notable contributions from National Grid and Texas Instruments.

Bert's August 2023 Dividend Income Summary

GET TO KNOW THE WOMEN-OWNED BUSINESSES RECEIVING GRANTS AND CONTRIBUTE TO THEIR SUCCESS, FURTHER CLOSING THE "CONFIDENCE GAP" IRVINE, Calif. , Sept. 6, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced the next chapter of the BOTOX® Cosmetic and IFundWomen grant program with the launch of crowdfunding campaigns for the women entrepreneurs.

Join BOTOX® Cosmetic (onabotulinumtoxinA) and IFundWomen in Supporting Women Entrepreneurs

NORTH CHICAGO, Ill. , Sept. 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023.

AbbVie to Present at the Morgan Stanley Healthcare Conference

Recursion Pharmaceuticals

Vertex Pharmaceuticals

In the grand tapestry of the investment world, one thread that continues to shine is biotech stocks to buy and hold. It's no secret that delving into biotech investments can be incredibly challenging, even when zeroing in on established firms with market-ready drugs and expansive research and development pipelines.

3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains

AbbVie has outperformed the S&P 500 since my previous update in early July, urging investors to buy despite market pessimism. AbbVie's prelim-Q2 earnings update likely spooked some investors to sell their shares at the lows. However, the company's robust actual Q2 performance helped calm undue fears. Investors unduly concerned about Humira's biosimilar erosion are not paying enough attention to the company's well-diversified portfolio.

AbbVie: Proving The Bears Wrong Again As Shares Surged

AbbVie has shown resilience and strength despite the patent loss of its best-selling drug, Humira. The company has reported impressive earnings, robust sales in various segments, and a promising pipeline. AbbVie offers a 4% dividend yield, steady dividend growth, and an attractive valuation, making it a top high-yield play.

AbbVie Unleashed: 4% Yield, Potentially 40% Undervalued

AbbVie's future growth depends on improving its balance of drugs offered, in contrast to its Humira-dependent first decade. Skyrizi and Rinvoq should offset the decline in Humira sales, but further growth depends on oncology and neuroscience as well as international sales growth in aesthetics. Even with this growth, ABBV stock should deliver around 8% total return annually through the end of the decade. This is in line with market performance making AbbVie a hold.

AbbVie: Balance Is Everything

Intellia Therapeutics

Despite polls showing most Americans are unhappy with the state of the economy, President Biden has defended his policies with claims he is improving the finances and living standards of minority voters. This commitment to economic inclusivity bodes well for overall economic health and long-term growth.

The 3 Most Promising Biotech Stocks to Own Now

Archer-Daniels-Midland Company

Black Hills

Gorman-Rupp

Lancaster Colony

Leggett & Platt

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of the Dow. The 50 Dividend Kings screened as of August 28, 2023, represented seven of eleven Morningstar Sectors. Broker targeted-top-ten net-gainers ranged 19.16%-33.65%, topped by Northwest Natural and Gorman-Rupp. By yield, Altria tops all. Top-ten Kingly September yields from NFG, ABBV, FRT, BKH, NWN, CDUAF, MMM, LEG, UVV, & MO averaged 5.51%.

Buy Ratings For 5 September Dividend Kings; Watch 4 More

News for AbbVie Stock (ABBV)